A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

Por Tang, H-J, Qian, D, Sondak, V K, Stachura, S, Lin, J
Publicado em 2004

Beyond BRAF: where next for melanoma therapy?

Por Fedorenko, I V, Gibney, G T, Sondak, V K, Smalley, K S M
Publicado no Br J Cancer (2015)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

Por Paraiso, K H T, Fedorenko, I V, Cantini, L P, Munko, A C, Hall, M, Sondak, V K, Messina, J L, Flaherty, K T, Smalley, K S M
Publicado em 2010

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma

Por DeConti, R C, Algazi, A P, Andrews, S, Urbas, P, Born, O, Stoeckigt, D, Floren, L, Hwang, J, Weber, J, Sondak, V K, Daud, A I
Publicado em 2010

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

Por Daud, A. I., Xu, C., Hwu, W.-J., Urbas, P., Andrews, S., Papadopoulos, N. E., Floren, L. C., Yver, A., DeConti, R. C., Sondak, V. K.
Publicado em 2010

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

Por Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Publicado em 2012

Genetic variations of the EVER genes, cutaneous human papillomavirus (HPV) infection, and squamous cell carcinoma of the skin

Por Hampras, S.S., Rollison, D.E., Tommasino, M., Gheit, T., Schabath, M.B., Messina, J.L., Fenske, N.A., Cherpelis, B.S., Sondak, V.K., Iannacone, M.R., Schmitt, M., Pawlita, M.
Publicado no Br J Dermatol (2015)